United States - English - NLM (National Library of Medicine)

macleods pharmaceuticals limited - quetiapine fumarate (unii: 2s3pl1b6uj) (quetiapine - unii:bgl0jsy5si) - quetiapine 150 mg - quetiapine extended-release tablets are indicated for the treatment of schizophrenia. the efficacy of quetiapine extended-release tablets in schizophrenia was established in one 6-week and one maintenance trial in adults with schizophrenia. efficacy was supported by three 6-week trials in adults with schizophrenia and one 6-week trial in adolescents with schizophrenia (13 to 17 years) treated with quetiapine [see clinical studies (14.1) ]. quetiapine  extended-release tablets are indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or divalproex. the efficacy of quetiapine  extended-release tablets in manic or mixed episodes of bipolar i disorder was established in one 3-week trial in adults with manic or mixed episodes associated with bipolar i disorder. efficacy was supported by two 12-week monotherapy trials and one 3-week adjunctive trial in adults with manic episodes associated with bipolar i disorder as well as

Canada - English - Health Canada

apotex inc - quetiapine (quetiapine fumarate) - tablet (immediate release) - 25mg - quetiapine (quetiapine fumarate) 25mg - atypical antipsychotics

Canada - English - Health Canada

apotex inc - quetiapine (quetiapine fumarate) - tablet (immediate release) - 100mg - quetiapine (quetiapine fumarate) 100mg - atypical antipsychotics

Canada - English - Health Canada

apotex inc - quetiapine (quetiapine fumarate) - tablet (immediate release) - 200mg - quetiapine (quetiapine fumarate) 200mg - atypical antipsychotics

Canada - English - Health Canada

apotex inc - quetiapine (quetiapine fumarate) - tablet (immediate release) - 300mg - quetiapine (quetiapine fumarate) 300mg - atypical antipsychotics

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - quetiapine fumarate -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - quetiapine fumarate -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - quetiapine fumarate -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - quetiapine fumarate -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 460.52 mg (equivalent: quetiapine, qty 400 mg) - tablet, modified release - excipient ingredients: carrageenan; light magnesium oxide; titanium dioxide; povidone; microcrystalline cellulose; macrogol 400; lactose monohydrate; magnesium stearate - bipolar disorder - maintenance treatment of bipolar 1 disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. treatment of depressive episodes associated with bipolar disorder (see dosage and administration). treatment of acute mania associated with bipolar i disorder as monotherapy or incombination with lithium or sodium valproate. efficacy of quetiapine in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets. schizophrenia - treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder (mdd)- treatment of recurrent major depressive disorde in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder (gad). treatment of generalised anxiety disorder.